pulmonary%20arterial%20hypertension
PULMONARY ARTERIAL HYPERTENSION
Pulmonary arterial hypertension is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in increased pulmonary vascular resistance and ultimately leading to right heart failure.
It is a part of the spectrum of pulmonary hypertension, which is hemodynamic and pathophysiological condition defined as an increase in mean pulmonary arterial pressure ≥25 mmHg at rest.
Typical symptoms include progressive dyspnea on exertion, palpitations, fatigue, weakness, angina, syncope and abdominal distention.

Introduction

  • A syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in increased pulmonary vascular resistance & remodeling, & ultimately leading to right heart failure

Definition

  • Pulmonary arterial hypertension (PAH) is part of the spectrum of pulmonary hypertension (PH), which is a hemodynamic & pathophysiological condition defined as an increase in mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest

Signs and Symptoms

Typical Symptoms

  • Progressive dyspnea on exertion, palpitations
  • Fatigue, weakness, angina, syncope, abdominal distention
  • Less commonly: Hemoptysis, Raynaud’s phenomenon

Risk Factors

Risk Factors & Associated Conditions for Pulmonary Arterial Hypertension (PAH)
Definite Causal Relationship Likely Causal Relationship Possible Causal Relationship Unlikely Causal Relationship
Drugs & Toxins Aminorex
Fenfluramine
Dexfenfluramine
Toxic grapeseed oil
Benfluorex
Selective serotonin reuptake inhibitor
Amphetamines
Dasatinib
L-tryptophan
Methamphetamine
Amphetamine-like drugs
Cocaine
Phenylpropanolamine
Chemotherapeutic agents (Mytomycin C, Cyclophosphamide)
Interferon α & β
St. John's Wort
Oral contraceptives
Estrogen therapy
Cigarette smoking
Demographic Factors Gender Pregnancy
Systemic hypertension
Obesity
Medical Conditions HIV infection
Severe symptomatic mitral or aortic valve disease
Portal hypertension or liver disease
Collagen vascular diseases
Congenital systemic-to- pumonary cardiac shunts
Thyroid disorders
Hematological conditions (eg asplenia 2° to surgical splenectomy, sickle cell disease, β-thalassemia, chronic myeloproliferative disorders)
Rare genetic or metabolic diseases (eg Type 1a glycogen storage disease, Gaucher's disease, hereditary hemorrhagic telangiectasia)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
22 May 2017
Chronic obstructive pulmonary disease (COPD) is currently the 10th commonest cause of death in Singapore, with a disease burden of 5.9 percent according to a 2015 population-based survey (EPIC-Asia survey) in Singapore. Pearl Toh spoke with Dr Augustine Tee, chief and senior consultant of the Department of Respiratory and Critical Care Medicine at Changi General Hospital (CGH) in Singapore, on how COPD is often underdetected in the primary care population as symptoms are not specific and diagnosis requires a combination of clinical risk factors, symptoms and spirometry testing.
15 Aug 2017
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
04 Aug 2017
Chronic obstructive pulmonary disease (COPD) is the fourth cause of global mortality, with experts predicting a potential future rise in the prevalence rates of COPD. 
11 May 2016

In conjunction with World Asthma Day which falls on 3rd May 2016, MIMS Doctor speaks to a renowned respiratory medicine specialist, Dato' Dr. Hj Abdul Razak Abdul Muttalif, regarding the chronic airway disease.